Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Br J Cancer. 2024 Mar;130(5):788-797. doi: 10.1038/s41416-023-02525-2. Epub 2024 Jan 10.
Br J Cancer. 2024.
PMID: 38200233
Free PMC article.
Clinical Trial.
A simple engineering alteration to IO access device electronics can lead to improved placement accuracy confirmation.
Vemu R, Yane TK, Glova GS, Paglia PL, Okyan K, Meaney DF, Chreiman K, Kaplan LJ, Pascual JL.
Vemu R, et al.
J Trauma Acute Care Surg. 2024 Apr 1;96(4):e28-e32. doi: 10.1097/TA.0000000000004214. Epub 2023 Nov 17.
J Trauma Acute Care Surg. 2024.
PMID: 37974330
No abstract available.
Item in Clipboard
TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.
McNerney KO, Karageorgos S, Ferry GM, Wolpaw AJ, Burudpakdee C, Khurana P, Toland CN, Vemu R, Vu A, Hogarty MD, Bassiri H.
McNerney KO, et al. Among authors: vemu r.
Oncoimmunology. 2022 May 24;11(1):2075204. doi: 10.1080/2162402X.2022.2075204. eCollection 2022.
Oncoimmunology. 2022.
PMID: 35646475
Free PMC article.
Item in Clipboard
Cite
Cite